NEW YORK (GenomeWeb) – Elucigene Diagnostics, a Manchester, UK-based molecular test provider, will seek US Food and Drug Administration clearance next year for a cystic fibrosis screening assay specific to the American population.

CEO Mark Street-Docherty said that the multiplexed PCR kit will target mutations associated with cystic fibrosis that are highly prevalent in the US.